The Neutrogena Sunscreen Benzene Verdict Answered One Question and Left Causation Untouched

The Neutrogena sunscreen benzene verdict decided one question and skipped the rest

On 15 September 2026, after a three-week trial, a jury in the Philadelphia Court of Common Pleas deliberated for roughly 90 minutes and returned a defense verdict for Kenvue, the former Johnson & Johnson Consumer Inc., in the first personal-injury case in the benzene sunscreen litigation ever to reach a verdict. The Neutrogena sunscreen benzene verdict turned on the first question on the verdict sheet — whether the aerosol sunscreen products the two decedents actually used were defective — and the jury answered no, which meant it never reached General Causation, Specific Causation, or damages at all.

That distinction is the entire story, and it is the part the coverage has compressed. A headline reporting that a company "beat claims its sunscreen caused cancer" describes a verdict that was never rendered. What twelve Philadelphia jurors decided, in less time than it takes to read the trial transcript of a single expert, was that the plaintiffs had not proved the bottles in their own bathrooms contained benzene. The science of benzene and acute myeloid leukemia was not adjudicated. The adequacy of Johnson & Johnson's warnings was not adjudicated. A batch-level evidentiary gap closed the case before any of that mattered.

For anyone valuing an inventory of contaminant claims — sunscreen, dry shampoo, benzoyl peroxide acne treatment, hand sanitizer — that is a more consequential result than a causation loss would have been. A causation defeat can be cured by better experts in the next case. A Product Identification defeat is structural: it recurs in every file where the consumer threw the can away.

What did the jury decide in the first Neutrogena sunscreen benzene trial?

The jury decided that the products were not defective, and decided nothing else. According to the trade report of the verdict, the panel answered "no" to the defect question and, under the structure of the verdict sheet, did not proceed to the questions on causation and damages that followed it.

The reported reasoning, drawn from the questions jurors sent out during their short deliberation, was specific to batches rather than to benzene generally: jurors concluded that the actual sunscreen products these two consumers purchased were not shown to be contaminated, and therefore that no manufacturing defect had been established. That is a finding about evidence, not about toxicology.

Element	What happened at trial
Court	Philadelphia Court of Common Pleas (Pennsylvania state court)
Verdict date	15 September 2026
Trial length	Approximately three weeks
Deliberation	Roughly 90 minutes
Plaintiffs	The estates of Amy Quinn and Betsy Skaroff, both deceased
Disease alleged	Acute myeloid leukemia
Product at issue	Neutrogena brand aerosol sunscreen
Defendant	Kenvue, formerly Johnson & Johnson Consumer Inc.
Question answered	Defect — answered no
Questions not reached	General Causation, Specific Causation, damages, Punitive Damages
Defense counsel	Alli Brown (Kirkland & Ellis); Mike Brown (Nelson Mullins Riley & Scarborough)
Significance	First personal-injury verdict in the benzene sunscreen litigation

A 90-minute deliberation after a three-week trial is itself data. Juries that wrestle with competing epidemiology take days. Juries that find a threshold proof failure take an afternoon. The speed here signals that the defect question was not close on the record the jury received, which matters more to the next trial team than the identity of the winner.

Who won the Neutrogena sunscreen benzene trial, and why?

Kenvue won, and it won on proof of contamination rather than on the merits of the benzene-leukemia hypothesis. The defense was tried by Alli Brown of Kirkland & Ellis and Mike Brown of Nelson Mullins Riley & Scarborough for the entity formerly known as Johnson & Johnson Consumer Inc.

Two features of the defense presentation are reported and both are transferable. First, on the hematology, the defense called clinicians who treat acute myeloid leukemia and put the genetic signature of benzene-associated leukemias in front of the jury, while the plaintiffs' side did not present a treating AML clinician. Second, and decisive, the defense pressed the batch question: benzene was not an ingredient in these products, and was detected in some samples and not others, so proof that a given consumer was exposed requires proof about that consumer's product.

The two lines reinforce each other. A jury told that only some lots ever tested positive, and then told by credentialed treating physicians what a benzene-caused leukemia looks like at the genetic level, has an easy path to a defect answer that avoids the harder scientific questions entirely. That is a defense architecture built to win at the first gate rather than the last.

Did the jury find that Neutrogena sunscreen caused cancer?

No — and it did not find the opposite either. The jury made no finding on whether benzene in aerosol sunscreen can cause acute myeloid leukemia, because the verdict sheet's structure meant the defect answer ended the deliberation before the causation questions were reached.

This is worth stating flatly because it is the point most readily lost. A defense verdict that stops at defect leaves the causation theory legally untested: no jury has accepted it, and no jury has rejected it. A future plaintiff with an intact product, a purchase record tied to a tested lot, or a recall-period exposure documented in a pharmacy record faces the same causation fight from the same starting line. Nothing about this verdict creates issue preclusion against anyone, and a verdict in a single state-court action does not bind other courts on any question of law or fact.

The recall, the Valisure petition, and the batch problem the verdict exposed

The litigation traces to two events in 2021. On 24 May 2021, the analytical pharmacy Valisure filed a citizen petition with the Food and Drug Administration reporting benzene in sunscreen and after-sun products. Its testing covered 294 unique batches; detectable benzene appeared in 78 products, of which 14 measured above 2 parts per million, 26 between 0.1 and 2.0 ppm, and 38 below 0.1 ppm. Of the 40 most contaminated products, 32 were sprays.

Then, on 14 July 2021, Johnson & Johnson Consumer Inc. voluntarily recalled all lots of five aerosol sunscreen lines to the consumer level after its own testing detected low levels of benzene in some samples: Neutrogena Beach Defense, Neutrogena CoolDry Sport, Neutrogena Invisible Daily Defense, Neutrogena UltraSheer, and Aveeno Protect + Refresh. The company's announcement made two points that would later become the spine of its defense — benzene is not an ingredient in any of the products, and it was detected in some samples of finished product rather than across the board — while stating that exposure at the levels detected would not be expected to cause adverse health consequences.

The regulatory record is not uniformly favorable to that last proposition. Consumer Reports later obtained an FDA Health Hazard Evaluation completed ahead of the recall which, on its reporting, found benzene levels in the products likely to cause serious adverse effects including "permanent impairment of a body function." The 2 ppm figure that recurs throughout this litigation is a reference level for an unavoidable contaminant in drug products, not a safety threshold for cosmetics, and the distinction is one plaintiffs' experts press and defense experts resist.

Read against the verdict, the 2021 record is double-edged. It supplies a documented contaminant, an admitted detection, a recall of every lot of five product lines, and an internal agency assessment that is worse than the public messaging. What it does not supply is a lot-by-lot map. "Some samples" is the operative phrase in the company's own announcement, and "some samples" is what beat these plaintiffs.

Date	Event
24 May 2021	Valisure files FDA citizen petition reporting benzene in 78 of 294 tested batches of sunscreen and after-sun products
14 July 2021	Johnson & Johnson Consumer Inc. recalls all lots of five aerosol lines — four Neutrogena, one Aveeno — after detecting benzene in some samples
8 October 2021	JPML forms MDL No. 3015 for the consumer marketing and sales-practices claims, assigned to Judge Raag Singhal in the Southern District of Florida
27 February 2023	District court grants final approval to the class settlement, including $1.75 million in vouchers for purchasers of non-recalled contaminated products
June 2024	Eleventh Circuit vacates that approval and remands for reconsideration of whether the vouchers are "coupons" under the Class Action Fairness Act (CAFA), following its decision in Drazen v. Pinto
3 July 2025	Objector Theodore Frank opposes renewed final approval on remand, noting roughly $2.6 million in requested fees against a voucher fund of which less than half was projected to be redeemed
15 September 2026	Philadelphia jury returns the first personal-injury verdict in the litigation, finding no defect

Product Identification is the choke point in every contaminant tort

The doctrinal lesson generalizes well beyond sunscreen. In a classic Design Defect case, every unit of the product shares the defect: a plaintiff who proves she used the drug or the device has proved she was exposed to the thing complained of. In a contaminant case, the defect lives in particular lots produced at particular times, which converts Product Identification from a formality into the central battleground.

Proof gate	Design-defect tort (e.g. a drug label case)	Contaminant tort (e.g. benzene in aerosol sunscreen)
Product use	Pharmacy or purchase record suffices	Same, but insufficient on its own
Exposure to the defect	Follows automatically from use	Requires linking the unit used to a contaminated lot
Evidence typically available	Prescription history, medical chart	Retail receipts, loyalty data, an unused can, third-party lot testing
Where the case can die early	Rarely before causation	At defect, before causation is reached
What a defense win establishes	Often something about the science	Often nothing about the science
Transferability of the loss	Curable with better experts	Recurs across the inventory

The pleading-stage history of these claims shows how the gate moved. In a Central District of California action brought by Kristi Hazard over a child's 2020 acute myeloid leukemia diagnosis following use of Neutrogena Beach Defense and Neutrogena UltraSheer aerosol products, Johnson & Johnson moved to dismiss and argued, among other things, that the complaint had to allege lot numbers, sun protection factor, bottle sizes and expiration dates, precisely because benzene had been detected only in certain batches. Judge Percy Anderson rejected that demand and let the case proceed.

The Philadelphia verdict is the other half of that story. What a plaintiff need not plead, a plaintiff must still prove. A batch argument that fails under Rule 12 because notice pleading does not require lot numbers succeeds in front of a jury that is entitled to ask whether this can, in this house, contained anything at all. Counsel who read the Hazard ruling as retiring the issue read it as a merits holding when it was a pleading holding.

Does the Philadelphia defense verdict end the sunscreen benzene lawsuits?

No. A single state-court verdict resolves the claims of two estates and binds no one else; the remaining personal-injury claims survive, the consumer class proceeding in MDL No. 3015 is unaffected, and the causation theory has not been tested, let alone rejected.

What the verdict does is reprice the inventory. Three concrete effects follow.

First, case selection tightens. Files where the claimant retained an unused container, kept receipts or loyalty records identifying a purchase within the recall window, or can tie a purchase to a lot with independent testing behind it are now worth materially more than files resting on brand recall alone. Firms that built inventories on advertising response rather than documentation will find the documented subset carrying the value of the whole.

Second, the settlement posture hardens on the defense side. A first trial win at the threshold gate, achieved in 90 minutes, is exactly the result that discourages a Global Settlement and encourages trying the next several cases. Claim Value in this litigation will now be set by however many defect findings each side can accumulate, not by the recall itself.

Third, the loss is not diagnostic of the science, and sophisticated defendants know it. That cuts both ways in negotiation: plaintiffs' counsel can argue with some force that no jury has yet rejected the causation case, while defense counsel can argue that the case that reached a jury never got far enough to need one.

Is there an MDL for sunscreen benzene personal injury claims?

Not a centralized federal one. The Judicial Panel on Multidistrict Litigation (JPML) created MDL No. 3015, In re Johnson & Johnson Aerosol Sunscreen Marketing, Sales Practices and Products Liability Litigation, on 8 October 2021, and assigned it to Judge Raag Singhal in the Southern District of Florida — but that Multidistrict Litigation (MDL) has functioned as the consumer economic-loss and marketing case, not as a personal-injury docket with a Bellwether Trial program, Plaintiff Fact Sheet (PFS) protocol and common-issue Daubert Challenge schedule.

That architecture explains the venue of the first trial. With no federal personal-injury MDL to funnel cases into, individual wrongful-death and survival actions have been filed and worked up one at a time in state courts and in scattered federal districts, and Philadelphia — a forum with a Complex Litigation Center and a track record of moving mass tort cases to trial quickly — got there first. Practitioners should not expect the discipline an MDL imposes: there is no Common Benefit Fund arrangement organizing the expert workup, no Lone Pine Order weeding thin files, and no single judge whose causation rulings set the terms for everyone.

The class side has its own history, and it is instructive about how modestly the consumer claims were valued. The MDL settlement approved on 27 February 2023 offered purchase-price refunds plus $1.75 million in vouchers for buyers of contaminated products that were not recalled, at a reported $10.58 per voucher and a household cap of two products, or $21.16. Objector Theodore Frank challenged it, and in June 2024 the Eleventh Circuit vacated final approval and remanded for the district court to decide whether the vouchers are "coupons" under the Class Action Fairness Act (CAFA) in light of Drazen v. Pinto — a question that governs how counsel fees, reported at roughly $2.6 million, may be calculated. Frank opposed renewed approval on remand in July 2025, and the approval question remains open on the public record.

The verdict lands in the middle of a wider contaminant-tort wave

Sunscreen is the first of these dockets to produce a personal-injury verdict, but it is not the only one built on the same evidentiary foundation. Benzene has since been reported in dry shampoo aerosols, in hand sanitizer, and in benzoyl peroxide acne treatments, where the mechanism is different again: benzoyl peroxide can degrade into benzene inside the product over time and at elevated temperature rather than arriving with a raw material. Valisure reported in March 2024 that some benzoyl peroxide acne products tested at benzene levels roughly 800 times the 2 ppm reference concentration. Six consumer class actions followed against L'Oreal over CeraVe and La Roche-Posay products — filed from February 2024, refused centralization in Hawaii by the JPML on 7 February 2025, and transferred to the Southern District of New York by May 2025, where at least one was dismissed on federal preemption grounds.

Every one of those litigations inherits the structural feature that decided the Philadelphia case. Because the offending substance is a contaminant rather than a listed ingredient, the plaintiff's proof has to reach the individual unit, and the defendant's own testing records — which show variation between lots and between samples within a lot — are simultaneously the best evidence that a problem existed and the best evidence that it did not exist everywhere. Degradation theories arguably make the plaintiff's task harder still, because a unit's benzene content then depends on how long it sat in a warehouse or a car, facts no consumer records.

Two practical implications follow for anyone building or defending these books of business. Contemporaneous third-party testing of retained product is the single most valuable piece of evidence a claimant can have, and it is worth more than any epidemiology the case will later need. And a defendant's public statement that a contaminant appeared in "some samples" is, in the hands of trial counsel, a defense exhibit as much as an admission.

What it means for plaintiffs' firms, defense counsel, and the Kenvue transaction

For plaintiffs' firms holding contaminant inventories. The economics of these dockets assume that exposure proof is cheap because the recall does the work. This verdict says it is not. The rational response is a documentation audit before the next trial slot: identify the subset of files with retained product, dated purchase evidence or lot-linked testing, and understand that the rest may be worth their Cost-of-Defence Settlement value rather than their advertised value. Firms carrying Third-Party Litigation Funding against these inventories should expect funders to ask which files clear the defect gate, because a case that dies at defect never reaches the Settlement Matrix that repayment models assume.

For defense counsel across the contaminant wave. The template is now public: contest defect first, keep the verdict sheet sequential so the defect answer is dispositive, and pair the batch argument with treating clinicians rather than pure epidemiologists. The same structure is available in the benzoyl peroxide acne-treatment cases now being filed against other cosmetic manufacturers, in dry shampoo, and in any product where the offending substance is a contaminant rather than an ingredient.

For claimants and their counsel in filed cases. The practical consequence is evidentiary, not legal. Nothing about this verdict shortens a Statute of Limitations, disqualifies a claim, or forecloses a theory. It raises the price of admission to the causation fight.

For the Kenvue–Kimberly-Clark transaction. Kenvue agreed to be acquired by Kimberly-Clark in a cash-and-stock deal valued at roughly $48.7 billion, with shareholder approval secured and closing expected in the fourth quarter of 2026. The sunscreen benzene docket sits alongside the prenatal acetaminophen litigation and residual talc exposures on the diligence list, and a threshold-gate defense verdict four days before the quarter's close is the kind of datapoint that firms up a reserve rather than moving a purchase price. It also demonstrates something acquirers care about more than any single result: that the liability can be defended on evidence the company itself generated in 2021.

Frequently asked questions

What did the jury decide in the first Neutrogena sunscreen benzene trial?

It decided that the aerosol sunscreen products the two decedents used were not defective, answering no to the first question on the verdict sheet on 15 September 2026 and going no further.

How long did the jury deliberate in the Kenvue sunscreen benzene case?

Roughly 90 minutes, following a trial of about three weeks in the Philadelphia Court of Common Pleas.

Did the jury find that Neutrogena sunscreen caused cancer?

No, and it made no finding either way: the defect answer ended the case before the jury reached General Causation, Specific Causation or damages.

Which sunscreens were recalled for benzene, and when?

On 14 July 2021, Johnson & Johnson Consumer Inc. recalled all lots of Neutrogena Beach Defense, Neutrogena CoolDry Sport, Neutrogena Invisible Daily Defense, Neutrogena UltraSheer and Aveeno Protect + Refresh aerosol sunscreens after detecting low levels of benzene in some samples.

What does a plaintiff have to prove in a benzene sunscreen lawsuit?

Beyond disease and damages, a plaintiff must establish that the specific unit used was contaminated — Product Identification tied to a lot — and then that benzene can cause the disease and did cause this claimant's disease.

Does the Philadelphia defense verdict end the sunscreen benzene lawsuits?

No: it resolves two estates' claims, binds no other claimant or court, leaves MDL No. 3015 and the remaining personal-injury filings intact, and settles no question of causation.

How does the verdict affect the Kimberly-Clark acquisition of Kenvue?

It is a diligence datapoint rather than a deal event: the roughly $48.7 billion transaction remains on track to close in the fourth quarter of 2026, and a win at the defect gate supports a smaller reserve for the sunscreen docket than a causation loss would have.